Eckert & Ziegler has entered into a global supply agreement with AtomVie Global Radiopharma to provide non-carrier-added lutetium-177 chloride (n.c.a. lu-177), branded as Theralugand, in support of AtomVie's radiopharmaceutical manufacturing services.

The Berlin-based isotope specialist will supply the radiotherapeutic isotope to AtomVie’s facility in Hamilton, Ontario, where the company operates as a contract development and manufacturing organization (CDMO). The partnership will support radiopharmaceutical development across both early- and late-stage programs, with provisions for global distribution.

According to the companies, the agreement is designed to adapt to evolving needs from AtomVie's pharmaceutical partners and aims to address regulatory compliance across international markets.
“We are happy to support AtomVie in advancing global radiopharmaceutical development programs with Theralugand,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler. “By providing our high-quality radionuclides, we vitally contribute to the further development of therapeutic approaches in nuclear medicine.”

AtomVie CEO Bruno Paquin said the agreement strengthens the company's capacity to meet increasing demand from clients developing Lutetium-177-based therapeutics.

“Partnering with Eckert & Ziegler is a significant step in ensuring that our global partners developing Lutetium-177-based radiopharmaceuticals have the support they need,” said Paquin. “With our new facility set to open later this year, this collaboration enhances our ability to provide reliable, high-quality manufacturing services.”

Lutetium-177 is increasingly used in targeted radiopharmaceutical therapies for various cancers, and secure supply chains for the isotope are a growing concern for manufacturers.

Eckert & Ziegler employs more than 1,000 staff and is listed on the TecDAX index of the Deutsche Börse. AtomVie currently supports clients conducting studies in more than 25 countries.

Rad Oncology Homepage